Weather Alert
Snow is in the forecast. Consider switching to a virtual visit to receive care from home. Learn more >>
Popular Search Terms
Melissa Burns, MD
Assistant Clinical Director, Hematologic Malignancy Program; Physician, Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Assistant Professor of Pediatrics, Harvard Medical School
Image
Melissa Burns, MD
Assistant Clinical Director, Hematologic Malignancy Program; Physician, Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Assistant Professor of Pediatrics, Harvard Medical School
Medical Services
Languages
English
Education
Medical School
New York Medical College
2009
Valhalla
NY
Internship
Boston Combined Residency Program (BCRP)
2010
Boston
MA
Residency
Boston Combined Residency Program (BCRP)
2012
Boston
MA
Fellowship
Pediatric Hematology-Oncology
Dana Farber Cancer Institute/Boston Children’s Hospital
2015
Boston
MA
Certifications
American Board of Pediatrics (General)
Publications
Vincristine Sulfate Liposome Injection With Combination Chemotherapy for Children, Adolescents, and Young Adults With Relapsed Acute Lymphoblastic Leukemia: A Therapeutic Advances in Childhood Leukemia and Lymphoma Consortium Trial. View Abstract
Activity of the MEK inhibitor trametinib in a patient with a BRAF mutation persisting from T-lymphoblastic lymphoma through lineage switch to CNS acute myeloid leukemia. View Abstract
Outcome for Children and Young Adults With T-Cell ALL and Induction Failure in Contemporary Trials. View Abstract
JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemia. View Abstract
Molecular basis of ETV6-mediated predisposition to childhood acute lymphoblastic leukemia. View Abstract
Corrigendum. View Abstract
Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001. View Abstract
Fanconi-BRCA pathway mutations in childhood T-cell acute lymphoblastic leukemia. View Abstract
Prohibitin is a prognostic marker and therapeutic target to block chemotherapy resistance in Wilms' tumor. View Abstract
PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia. View Abstract
Hedgehog pathway mutations drive oncogenic transformation in high-risk T-cell acute lymphoblastic leukemia. View Abstract
Reduction of spinning sidebands in proton NMR of human prostate tissue with slow high-resolution magic angle spinning. View Abstract
Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy. View Abstract
Quantitative pathology in tissue MR spectroscopy based human prostate metabolomics. View Abstract